Haleon is investing Rs 2,000 crore to build its first manufacturing plant in Pithampur, India. This move sharpens its focus on India, a fast-growing consumer healthcare market. The plant will produce oral-health products, including Sensodyne. It aims to reach one billion more consumers by 2030, with 300 million in India. The facility will also cater to export markets.

Haleon announces ₹2,000 crore investment to establish its first manufacturing facility in India, enhancing local oral care production and exports.

Haleon, the maker of Sensodyne, will invest £175 million to build its first oral health manufacturing plant in India, signaling strong confidence in the country's market potential.

NEW DELHI: Haleon, formerly GSK Consumer Healthcare, will invest about Rs 2,000 crore (£175 million) to establish its first manufacturing facility in India, underscoring the…